Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes

MR Taskinen; E Bjornson; J Kahri; S Soderlund; N Matikainen; K Porthan; M Ainola; A Hakkarainen; N Lundbom; V Fermanelli; J Fuchs; A Thorsell; F Kronenberg; L Andersson; M Adiels; CJ Packard; J Boren

doi:10.1161/ATVBAHA.120.315446

Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes

MR Taskinen, E Bjornson, J Kahri, S Soderlund, N Matikainen, K Porthan, M Ainola, A Hakkarainen, N Lundbom, V Fermanelli, J Fuchs, A Thorsell, F Kronenberg, L Andersson, M Adiels, CJ Packard, J Boren

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Arteriosclerosis, Thrombosis, and Vascular Biology
Volume	41
Issue number	2
Pages (from-to)	962-975
Number of pages	14
ISSN	1079-5642
DOIs	https://doi.org/10.1161/ATVBAHA.120.315446
Publication status	Published - Feb 2021
MoE publication type	A1 Journal article-refereed

Fields of Science

apolipoprotein
cardiovascular diseases
chylomicrons
evolocumab
kinetics
TRIGLYCERIDE-RICH LIPOPROTEINS
PCSK9 INHIBITOR EVOLOCUMAB
SUBTILISIN/KEXIN TYPE 9
CARDIOVASCULAR-DISEASE
000 PARTICIPANTS
LDL CHOLESTEROL
REDUCING LIPIDS
EFFICACY
SAFETY
METABOLISM
3121 General medicine, internal medicine and other clinical medicine

Access to Document

10.1161/ATVBAHA.120.315446

Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 DiabetesFinal published version, 1.71 MBLicence: CC BY

Cite this

Taskinen, MR., Bjornson, E., Kahri, J., Soderlund, S., Matikainen, N., Porthan, K., Ainola, M., Hakkarainen, A., Lundbom, N., Fermanelli, V., Fuchs, J., Thorsell, A., Kronenberg, F., Andersson, L., Adiels, M., Packard, CJ., & Boren, J. (2021). Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 41(2), 962-975. https://doi.org/10.1161/ATVBAHA.120.315446

@article{e5f129bea95c4b6baad95341a3e224f9,

title = "Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes",

keywords = "apolipoprotein, cardiovascular diseases, chylomicrons, evolocumab, kinetics, TRIGLYCERIDE-RICH LIPOPROTEINS, PCSK9 INHIBITOR EVOLOCUMAB, SUBTILISIN/KEXIN TYPE 9, CARDIOVASCULAR-DISEASE, 000 PARTICIPANTS, LDL CHOLESTEROL, REDUCING LIPIDS, EFFICACY, SAFETY, METABOLISM, 3121 General medicine, internal medicine and other clinical medicine",

author = "MR Taskinen and E Bjornson and J Kahri and S Soderlund and N Matikainen and K Porthan and M Ainola and A Hakkarainen and N Lundbom and V Fermanelli and J Fuchs and A Thorsell and F Kronenberg and L Andersson and M Adiels and CJ Packard and J Boren",

year = "2021",

month = feb,

doi = "10.1161/ATVBAHA.120.315446",

language = "English",

volume = "41",

pages = "962--975",

journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",

issn = "1079-5642",

publisher = "Lippincott williams & wilkins",

number = "2",

}

Taskinen, MR, Bjornson, E, Kahri, J , Soderlund, S , Matikainen, N, Porthan, K, Ainola, M , Hakkarainen, A , Lundbom, N, Fermanelli, V, Fuchs, J, Thorsell, A, Kronenberg, F, Andersson, L, Adiels, M, Packard, CJ & Boren, J 2021, 'Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 41, no. 2, pp. 962-975. https://doi.org/10.1161/ATVBAHA.120.315446

TY - JOUR

T1 - Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes

AU - Taskinen, MR

AU - Bjornson, E

AU - Kahri, J

AU - Soderlund, S

AU - Matikainen, N

AU - Porthan, K

AU - Ainola, M

AU - Hakkarainen, A

AU - Lundbom, N

AU - Fermanelli, V

AU - Fuchs, J

AU - Thorsell, A

AU - Kronenberg, F

AU - Andersson, L

AU - Adiels, M

AU - Packard, CJ

AU - Boren, J

PY - 2021/2

Y1 - 2021/2

KW - apolipoprotein

KW - cardiovascular diseases

KW - chylomicrons

KW - evolocumab

KW - kinetics

KW - TRIGLYCERIDE-RICH LIPOPROTEINS

KW - PCSK9 INHIBITOR EVOLOCUMAB

KW - SUBTILISIN/KEXIN TYPE 9

KW - CARDIOVASCULAR-DISEASE

KW - 000 PARTICIPANTS

KW - LDL CHOLESTEROL

KW - REDUCING LIPIDS

KW - EFFICACY

KW - SAFETY

KW - METABOLISM

KW - 3121 General medicine, internal medicine and other clinical medicine

U2 - 10.1161/ATVBAHA.120.315446

DO - 10.1161/ATVBAHA.120.315446

M3 - Article

SN - 1079-5642

VL - 41

SP - 962

EP - 975

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

IS - 2

ER -